Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance.
“As Tocagen continues to enroll patients in Toca 5, our Phase 2/3 clinical trial in patients with recurrent high grade glioma, Wood’s expertise and insights will be extremely beneficial,” stated Harry Gruber CEO at Tocagen.
The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial.Watch Full Movie Online Streaming Online and Download
With more than 20 years of regulatory affairs experience, Wood joined from Arena Pharmaceuticals, where he played an integral role interfacing with Eisai Inc. regarding regulatory strategy for life cycle management for BELVIQ®. Previous to this role, he led regulatory affairs and alliance management at Amylin Pharmaceuticals.
Last June, Tocagen appointed Asha Das as vice president of clinical development and medical affairs.